Pure Global
NCT06211023

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

An Open-label, Randomized, Controlled, Phase II/III Study of SHR-A1921 With or Without Carboplatin Verus Investigator's Choice of Platinum-based Doublet Chemotherapy in Patients With Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2/3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
SHR-1921
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Timeline & enrollment
Phase
Phase 2/3
Start date
Feb 15, 2024
End date
Jun 15, 2026
Enrollment
520 participants
Primary outcome

Objective Response Rate Assessed by Investigator According to RECIST v1.1

Summary

This is an open-label, randomized, controlled, two-part study to evaluate the safety and
 efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of
 platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06211023
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06211023 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 520 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.